Considering the other (preclinical) data for PRGN-3005, 3006 and 3007, I wouldn't read much, if anything into it. Also, by now, you would think that the company would have translational data from the two ongoing trials, which could help inform them as to why genes they might silence next, using (from memory) miRNA.
Market Data 
Markets 
AI
